Table 1.

CHEK2*1100delC in breast cancer cases and healthy controls

	Positive for CHEK2*1100delC (%)
Controls
Jewish (New York)	3/1096 (0.3%)
Non-Jewish (New York)	2/569 (0.4%)
Total	5/1665 (0.3%)
BRCA1/2-negative individuals of mixed ethnicity with breast cancer from families with 3 or more cases of breast cancer	0/67 (0.0%)
BRCA1/2 Ashkenazi founder mutation-negative individuals with breast cancer from families with 3 or more cases of breast cancer	1/33# (3.0%)
BRCA2-negativei individuals of mixed ethnicity with male breast cancer	0/16 (0.0%)
Individuals with bilateral breast cancer of mixed ethnicity unselected for family history	0/46 (0.0%)
Individuals with unilateral breast cancer unselected for family history matched for age, ethnicity	1/46 (2.2%)
Clinic-ascertained individuals of Ashkenazi Jewish descent with bilateral breast cancer	1/46 (2.2%)
Clinic-ascertained individuals of Ashkenazi Jewish descent with unilateral breast cancer matched for age, family history	0/46 (0.0%)

^#This case previously reported in CHEK2 Breast Cancer Consortium [5].